These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21303373)

  • 1. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
    Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
    Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
    Lee JJ; Kook H; Park MS; Nam JH; Choi BH; Song WH; Park KS; Lee IK; Chung IJ; Hwang TJ; Kim HJ
    J Clin Apher; 2004; 19(2):66-70. PubMed ID: 15274198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells.
    Köhler T; Plettig R; Wetzstein W; Schmitz M; Ritter M; Mohr B; Schaekel U; Ehninger G; Bornhäuser M
    Stem Cells; 2000; 18(2):139-47. PubMed ID: 10742386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
    Zhong RK; Lane TA; Ball ED
    Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can leukemia-derived dendritic cells generate antileukemia immunity?
    Rosenblatt J; Avigan D
    Expert Rev Vaccines; 2006 Aug; 5(4):467-72. PubMed ID: 16989627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia.
    Schmitt A; Reinhardt P; Hus I; Tabarkiewicz J; Roliñski J; Barth T; Giannopoulos K; Dmoszyñska A; Wiesneth M; Schmitt M
    Transfusion; 2007 Sep; 47(9):1588-94. PubMed ID: 17725721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.
    Blaser BW; Caligiuri MA
    Best Pract Res Clin Haematol; 2006; 19(2):281-92. PubMed ID: 16516125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
    Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
    Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
    He X; You S; Bian S
    Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of dendritic cells from acute myeloid leukaemia cells and monocytes: our local experience.
    Lim MN; Leong CF; Cheong SK; Seow HF
    Malays J Pathol; 2003 Dec; 25(2):107-12. PubMed ID: 16196366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2006 Mar; 91(3):348-55. PubMed ID: 16531258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
    Yang T; Chen ZZ; Kolb HJ; Buhmann R
    Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.